2-Apr-2026
Codexis (CDXS) Gets a Buy from Jefferies
TipRanks (Wed, 1-Apr 2:35 PM ET)
Market Chameleon (Thu, 12-Mar 5:52 AM ET)
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Globe Newswire (Wed, 11-Mar 4:05 PM ET)
Market Chameleon (Thu, 5-Mar 6:08 AM ET)
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform
PRNewswire (Wed, 4-Mar 10:06 AM ET)
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Globe Newswire (Wed, 25-Feb 9:00 AM ET)
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 17-Feb 9:00 AM ET)
Codexis Achieves ISO 9001:2015 Certification
Globe Newswire (Tue, 10-Feb 9:00 AM ET)
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Codexis trades on the NASDAQ stock market under the symbol CDXS.
As of April 2, 2026, CDXS stock price climbed to $1.82 with 756,772 million shares trading.
CDXS has a beta of 2.02, meaning it tends to be more sensitive to market movements. CDXS has a correlation of 0.18 to the broad based SPY ETF.
CDXS has a market cap of $165.38 million. This is considered a Micro Cap stock.
Last quarter Codexis reported $39 million in Revenue and $.11 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.15.
In the last 3 years, CDXS traded as high as $6.08 and as low as $.96.
The top ETF exchange traded funds that CDXS belongs to (by Net Assets): IWM, VTI, IBB, IWO, VXF.
CDXS has underperformed the market in the last year with a return of -26.9%, while SPY returned +17.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CDXS shares. However, CDXS has outperformed the market in the last 3 month and 2 week periods, returning +13.0% and +9.0%, while SPY returned -3.7% and -0.1%, respectively. This indicates CDXS has been having a stronger performance recently.
CDXS support price is $1.61 and resistance is $1.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDXS shares will trade within this expected range on the day.